Jan 11, 2024 / 08:00PM GMT
Sanjee Vita JPMorgan-Analyst
Welcome, everyone. I'm [Sanjee Vita] with JPMorgan Healthcare and we are pleased to have with us Taylor Schreiber, MD, PhD, Co-Founder and CEO of Shattuck Labs. For logistic purposes, please reserve any questions that you may have till the end of the presentation. And with that, I will let Taylor have the stage.
Taylor Schreiber Shattuck Labs Inc-Chief Executive Officer and Cofounder
Great. Good afternoon everybody. Thanks to the JPMorgan Group for the invitation to present at the 2024 Healthcare Conference. These are my forward-looking statements. So the content of today's presentation will focus on our lead clinical asset. We call it SL-172154. I'll explain the structure of this compound in the next slide.
This is a SIRP-alpha-Fc-CD40 ligand dual sided fusion protein and throughout today's presentation, I'll refer to this simply as 154. The structure of 154 is shown in the schematic in the middle of this slide, and on the upper portion of the molecule in orange, we have at the extracellular domain of the
Shattuck Labs Inc at JPMorgan Healthcare Conference Transcript
Jan 12, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers